Leukemia (chronic myeloic)

Warning: Undefined array key "S1" in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Leukemia (chronic myeloic).php on line 2
Leukemia (chronic myeloic)

LE WE PMID CA

Leukemia (chronic myeloic)

1588

Leukaemie (chronisch myeloische)

Dasatinib

Essential thrombocythemia

Hemophagocytosis

Hypereosinophilic syndrome

Imatinib

JAK2V617F

Leukemia (chronic myeloic)

Leukemia (chronic neutrophilic)

Mastocytosis

Myelofibrosis

Myeloproliferative syndromes

Neoplasia (Minimal residual disease)

Nilotinib

Polycythemia vera

Stem cell (Neoplasia)

TET2

2008 1	Chronic myeloid leukaemia: the evolution of gene-targeted therapy. [18759727] Med J Aust 189(5): 277-82 (2008)
2010 2	Chronic myelogenous leukemia: treatment and monitoring. [20221270] Dtsch Arztebl Int 107(7): 114-21 (2010)
2007 3	Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance. [19707322] Biologics 1(2): 121-7 (2007)
2003 4	Specific targeted therapy of chronic myelogenous leukemia with imatinib. [12869662] Pharmacol Rev 55(3): 401-23 (2003)
2009 5	Dasatinib in chronic myeloid leukemia: a review. [19536317] Ther Clin Risk Manag 5(2): 281-9 (2009)
2010 6	Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review. [20694077] Core Evid 4(-): 207-13 (2010)
2009 7	Treatment selection after imatinib resistance in chronic myeloid leukemia. [19343297] Target Oncol 4(1): 3-10 (2009)
2008 8	Chronic myelogenous leukemia: ESMO clinical recommendations for the diagnosis, treatment and follow-up. [18456772] Ann Oncol 19 Suppl 2(-): ii63-4 (2008)
2007 9	Advances in the treatment of haematological malignancies: optimal sequence of CML treatment. [17631597] Ann Oncol 18 Suppl 9(-): ix58-63 (2007)
2008 10	Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications. [18348294] Cancer 112(10): 2112-8 (2008)
2007 11	Current and emerging treatment options in chronic myeloid leukemia. [17431887] Cancer 109(11): 2171-81 (2007)
2003 12	Chronic myelogenous leukemia: a review and update of therapeutic strategies. [12879460] Cancer 98(3): 437-57 (2003)
2009 13	Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities. [19337201] Cancer Control 16(2): 153-7 (2009)
2009 14	The biological basis for immunotherapy in patients with chronic myelogenous leukemia. [19337200] Cancer Control 16(2): 141-52 (2009)
2009 15	Chronic myeloid leukemia therapy: focus on second-generation tyrosine kinase inhibitors. [19337199] Cancer Control 16(2): 132-40 (2009)
2009 16	Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. [19337198] Cancer Control 16(2): 122-31 (2009)
2009 17	Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia. [19337197] Cancer Control 16(2): 108-21 (2009)
2009 18	Signaling networks associated with BCR-ABL-dependent transformation. [19337196] Cancer Control 16(2): 100-7 (2009)
2001 19	NCCN: Chronic myelogenous leukemia. [11760557] Cancer Control 8(6 Suppl 2): 44-8 (2001)
2002 20	Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. [12006504] Clin Cancer Res 8(5): 935-42 (2002)
2002 21	BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. [12476311] Oncogene 21(56): 8652-67 (2002)
2002 22	Studying the pathogenesis of BCR-ABL+ leukemia in mice. [12476310] Oncogene 21(56): 8643-51 (2002)
2002 23	The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model. [12476309] Oncogene 21(56): 8629-42 (2002)
2002 24	The biology of chronic myelogenous leukemia:mouse models and cell adhesion. [12476308] Oncogene 21(56): 8612-28 (2002)
2002 25	Mechanisms underlying abnormal trafficking and expansion of malignant progenitors in CML: BCR/ABL-induced defects in integrin function in CML. [12476307] Oncogene 21(56): 8605-11 (2002)
2002 26	BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. [12476306] Oncogene 21(56): 8591-604 (2002)
2002 27	Post-transcriptional mechanisms in BCR/ABL leukemogenesis: role of shuttling RNA-binding proteins. [12476304] Oncogene 21(56): 8577-83 (2002)
2002 28	Transforming pathways activated by the v-Abl tyrosine kinase. [12476303] Oncogene 21(56): 8568-76 (2002)
2002 29	Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia. [12476302] Oncogene 21(56): 8560-7 (2002)
2002 30	BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia. [12476301] Oncogene 21(56): 8547-59 (2002)
2002 31	Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. [12476300] Oncogene 21(56): 8541-6 (2002)
2002 32	Philadelphia-positive leukemia: a personal perspective. [12476299] Oncogene 21(56): 8536-40 (2002)
2002 33	Chronic myelogenous leukemia: mechanisms underlying disease progression. [12145676] Leukemia 16(8): 1402-11 (2002)
2002 34	Tyrosine kinase fusion genes in chronic myeloproliferative diseases. [12094244] Leukemia 16(7): 1207-12 (2002)
1999 35	Cell biology of CML cells. [10232368] Leukemia 13 Suppl 1(-): S65-71 (1999)
2009 36	First-line therapy for chronic myeloid leukemia: Past, present, and future. [19306355] Am J Hematol 84(5): 287-93 (2009)
2008 37	Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. [17957805] Am J Hematol 83(4): 296-302 (2008)
2005 38	Erythrophagocytosis by dysplastic neutrophils in chronic myelomonocytic leukemia and subsequent transformation to acute myeloid leukemia. [16044446] Am J Hematol 79(4): 340-2 (2005)
1999 39	Chronic myelogenous leukemia: biology and therapy. [10428738] Ann Intern Med 131(3): 207-19 (1999)
2008 40	Translation of the Philadelphia chromosome into therapy for CML. [19064740] Blood 112(13): 4808-17 (2008)
2008 41	Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. [18055868] Blood 111(4): 1774-80 (2008)
2007 42	How I treat chronic myeloid leukemia in the imatinib era. [17626839] Blood 110(8): 2828-37 (2007)
2006 43	Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. [16709930] Blood 108(6): 1809-20 (2006)
2006 44	Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. [16522812] Blood 108(1): 28-37 (2006)
2005 45	The development of imatinib as a therapeutic agent for chronic myeloid leukemia. [15618470] Blood 105(7): 2640-53 (2005)
2004 46	The biology of CML blast crisis. [14982876] Blood 103(11): 4010-22 (2004)
2001 47	Chronic myeloid leukemia: current treatment options. [11567987] Blood 98(7): 2039-42 (2001)
2000 48	The molecular biology of chronic myeloid leukemia. [11071626] Blood 96(10): 3343-56 (2000)
1993 49	Chronic myelogenous leukemia: a concise update. [8338938] Blood 82(3): 691-703 (1993)
1985 50	Chronic myelogenous leukemia: recent advances. [2581632] Blood 65(5): 1039-47 (1985)
2008 51	Treatment of chronic myeloid leukemia in blast crisis. [19050065] Haematologica 93(12): 1765-9 (2008)
2008 52	Monitoring treatment of chronic myeloid leukemia. [18245647] Haematologica 93(2): 161-9 (2008)
1996 53	Pathogenesis and progression of chronic myeloid leukemia. [8900856] Haematologica 81(1): 63-76 (1996)
2009 54	Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. [20008232] Hematology Am Soc Hematol Educ Program -(-): 461-76 (2009)
2008 55	Novel agents in CML therapy: tyrosine kinase inhibitors and beyond. [19074121] Hematology Am Soc Hematol Educ Program -(-): 427-35 (2008)
2008 56	Milestones and monitoring in patients with CML treated with imatinib. [19074120] Hematology Am Soc Hematol Educ Program -(-): 419-26 (2008)
2007 57	The Biology of CML blast crisis. [18024655] Hematology Am Soc Hematol Educ Program -(-): 384-91 (2007)
2007 58	Medical management of CML. [18024653] Hematology Am Soc Hematol Educ Program -(-): 371-5 (2007)
2006 59	Defining and managing imatinib resistance. [17124064] Hematology Am Soc Hematol Educ Program -(-): 219-25 (2006)
2006 60	ABL kinase inhibitor therapy for CML: baseline assessments and response monitoring. [17124063] Hematology Am Soc Hematol Educ Program -(-): 211-8 (2006)
2004 61	Chronic myelogenous leukemia and myeloproliferative disease. [15561681] Hematology Am Soc Hematol Educ Program -(-): 146-62 (2004)
2003 62	Chronic myeloproliferative disorders. [14633783] Hematology Am Soc Hematol Educ Program -(-): 200-24 (2003)
2003 63	Chronic myeloid leukemia. [14633780] Hematology Am Soc Hematol Educ Program -(-): 132-52 (2003)
2002 64	Chronic myelogenous leukemia. [12446421] Hematology Am Soc Hematol Educ Program -(-): 111-35 (2002)
2001 65	Chronic myelogenous leukemia. [11722980] Hematology Am Soc Hematol Educ Program -(-): 87-112 (2001)
2002 66	Current therapy of chronic myelogenous leukemia. [11993784] Intern Med 41(4): 254-64 (2002)
2007 67	Applying the discovery of the Philadelphia chromosome. [17671641] J Clin Invest 117(8): 2067-74 (2007)
2007 68	Treatment for chronic myelogenous leukemia: the long road to imatinib. [17671637] J Clin Invest 117(8): 2036-43 (2007)
2007 69	Discovery of the Philadelphia chromosome: a personal perspective. [17671636] J Clin Invest 117(8): 2033-5 (2007)
2007 70	The legacy of the Philadelphia chromosome. [17671635] J Clin Invest 117(8): 2030-2 (2007)
2009 71	Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? [19181650] Mayo Clin Proc 84(2): 161-9 (2009)
2006 72	Chronic myeloid leukemia: diagnosis and treatment. [16835977] Mayo Clin Proc 81(7): 973-88 (2006)
2006 73	Stem cell transplantation in patients with chronic myelogenous leukemia: when should it be used? [16529146] Mayo Clin Proc 81(3): 404-16 (2006)
2005 74	bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment. [16178503] Mayo Clin Proc 80(9): 1220-32 (2005)
2005 75	Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. [15757021] Mayo Clin Proc 80(3): 390-402 (2005)
2002 76	Isolated umbilical endometriosis--a rare finding. [12751574] Afr J Med Med Sci 31(3): 281-2 (2002)
1976 77	[Periarteritis nodosa. Apropos of 12 cases]. [9671] Rev Clin Esp 142(3): 217-22 (1976)
2011 78	Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors. [21411987] Acta Haematol 126(1): 30-9 (2011)
2010 79	Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. [20555071] Ann Oncol 21 Suppl 5(-): v165-7 (2010)
2009 80	Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up. [19454424] Ann Oncol 20 Suppl 4(-): 105-7 (2009)
2010 81	Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia. [20184539] Anticancer Agents Med Chem 10(2): 111-5 (2010)
2009 82	Chronic myelogenous leukemia, BCR-ABL1+. [19605820] Am J Clin Pathol 132(2): 250-60 (2009)
2009 83	Philadelphia chromosome-negative chronic myeloproliferative disease. [19605821] Am J Clin Pathol 132(2): 261-80 (2009)
2009 84	Molecular biology of bcr-abl1-positive chronic myeloid leukemia. [18827185] Blood 113(8): 1619-30 (2009)
2009 85	How I monitor residual disease in chronic myeloid leukemia. [19661271] Blood 114(16): 3376-81 (2009)
2011 86	The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues. [21242185] Haematologica 96(4): 590-601 (2011)
2011 87	Mutant BCR-ABL clones in chronic myeloid leukemia. [21357713] Haematologica 96(3): 347-9 (2011)
2010 88	Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation. [21239821] Hematology Am Soc Hematol Educ Program 2010(-): 368-76 (2010)
2010 89	Chronic myeloid leukemia 2010: where are we now and where can we go? [21239781] Hematology Am Soc Hematol Educ Program 2010(-): 122-8 (2010)
2007 90	Chronic myeloid leukemia: molecular monitoring in clinical practice. [18024654] Hematology Am Soc Hematol Educ Program -(-): 376-83 (2007)
2009 91	Initial treatment for patients with CML. [20008231] Hematology Am Soc Hematol Educ Program -(-): 453-60 (2009)
2010 92	Chronic myeloid leukemia: mechanisms of blastic transformation. [20592475] J Clin Invest 120(7): 2254-64 (2010)
2009 93	A new era in the treatment of chronic myeloid leukemia. [19337195] Cancer Control 16(2): 96-7 (2009)
2008 94	Myeloproliferative syndromes: diagnosis and therapeutic options. [19202955] Pol Arch Med Wewn 118(12): 756-60 (2008)
2010 95	First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. [21108851] J Hematol Oncol 3(-): 47 (2010)
2008 96	P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. [18828913] J Hematol Oncol 1(-): 15 (2008)
2010 97	Stem cell transplant for chronic myeloid leukemia in the imatinib era. [20875552] Semin Hematol 47(4): 354-61 (2010)
2007 98	The chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54 year old speculation comes of age. [17336249] Best Pract Res Clin Haematol 20(1): 5-12 (2007)
2011 99	Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML. [21792346] Clin Med Insights Oncol 5(-): 185-99 (2011)
2010 100	Critical molecular pathways in cancer stem cells of chronic myeloid leukemia. [20574455] Leukemia 24(9): 1545-54 (2010)
2010 101	Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors--the first molecular targeted treatment. [20968202] J Med Life 3(2): 162-6 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Leukemia (chronic myeloic).php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Leukemia (chronic myeloic).php on line 92